Tumors develop through successive stages characterized by changes in gene expression and protein function. Gene expression profiling of pancreatic islet tumors in a mouse model of cancer revealed upregulation of cathepsin cysteine proteases. Cathepsin activity was assessed using chemical probes allowing biochemical and in vivo imaging, revealing increased activity associated with the angiogenic vasculature and invasive fronts of carcinomas, and differential expression in immune, endothelial, and cancer cells. A broad-spectrum cysteine cathepsin inhibitor was used to pharmacologically knock out cathepsin function at different stages of tumorigenesis, impairing angiogenic switching in progenitor lesions, as well as tumor growth, vascularity, and invasiveness. Cysteine cathepsins are also upregulated during HPV16-induced cervical carcinogenesis, further encouraging consideration of this protease family as a therapeutic target in human cancers.
Introduction
of which a subset ‫)%52ف(‬ subsequently acquire the ability to switch on angiogenesis (Folkman et al., 1989) . A subset of these angiogenic islets (15%-20%) develop into tumors; both benign, Cancer is a complex set of proliferative diseases that are thought encapsulated lesions and invasive carcinomas (Lopez and to arise in most cases via multistep pathways involving an accu- . This multistage pathway suggests the sequenmulation of genetic and epigenetic changes, including inactivatial involvement of multiple rate-limiting genetic and epigenetic tion of tumor suppressor genes and activation of oncogenes events in the progression from normal cells to tumors. (Hanahan and Weinberg, 2000; Kinzler and Vogelstein, 1996) .
To define novel molecular pathways to cancer, we sought The development of tumors can be separated into a series to profile changes in gene expression in each of the lesional of distinct clinical, histological, and temporal stages. Mouse stages of sequential tumor development in RIP1-Tag2 mice. models of multistage carcinogenesis allow the study of the moWe present evidence that a subset of papain family Clan CA lecular basis of this process, and the identification and characcysteine proteases known as cathepsins make an important terization of molecular effectors of cancer in many organs (Wu contribution to the development of islet tumors. The traditional and Pandolfi, 2001) .
term "cathepsin" includes serine, cysteine, and aspartyl type RIP1-Tag2 transgenic mice develop multiple pancreatic islet proteases. The work presented here focuses on the cysteine tumors by 12-14 weeks of age, as a consequence of expressing cathepsin family, which comprises 11 human members to date the SV40 T antigen (Tag) oncogenes in insulin-producing ␤ cells (cathepsins B, C, H, F, K, L, O, S, V, W, and X/Z) (Turk et al., (Hanahan, 1985) . Tumor development in these mice proceeds 2002), and will be collectively abbreviated hereafter simply as through a series of discrete stages, in which approximately 50%
cathepsins. These cathepsins are primarily intracellular proteases that function in terminal protein degradation in lysosomes of the ‫004ف‬ islets in the pancreas become hyperproliferative, (Turk et al., 2001 ) and protein processing in other intracellular progressive increase in overall levels of cathepsin activity during organelles (e.g., hormone secretory granules [Yasothornsrikul RIP1-Tag2 tumorigenesis ( Figure 1C ). Individual bands from et al., 2003] ). However, cathepsins have specific roles in physiowhole tumor lysates were resolved by 1D gel electrophoresis logical processes, including bone remodeling, epidermal ho-(data not shown), and identified by single-step purification using meostasis, and antigen presentation (reviewed in Turk et al., the biotin tag, followed by mass spectrometry-based sequenc-2002). Enzymes of this group can be found at the cell surface, ing. Cathepsins B, C, L, and Z ( Figure 1C ) were identified by both in T cells (Balaji et al., 2002) and in certain tumors (reviewed their sequence, and their identities confirmed by immunoprecipin Roshy et al., 2003) , and in some cases are secreted (Brix et itation experiments with antibodies recognizing individual caal., 2001; Koblinski et al., 2002; Mort et al., 1985; thepsins (data not shown). The specificity of the ABP was conal., 1985) . Surveys of human tumors have suggested an associafirmed by competition experiments using a broad-spectrum tion of certain cathepsins with malignancy (Lah and Kos, 1998;  cathepsin cysteine protease inhibitor, JPM-OEt (Meara and Rao, 2003; Yan et al., 1998) , but this class of proteases has Rich, 1996) ( Figure 1B) , and a cathepsin B-specific inhibitor, not been a prominent target for anticancer therapies, in contrast MB-074 (Bogyo et al., 1999) . Preincubation of tumor lysates with to the matrix metalloproteases. We show here using small mole-JPM-OEt completely abolished DCG-04 labeling of all active cule inhibitors and activity based probes that cathepsin activity cathepsins in the 20-40 kDa range (lane 2, Figure 1D ). Likewise, is increased during tumorigenesis and that inhibition of catheppretreatment with MB-074 specifically blocked cathepsin B acsin function impairs tumor development. tivity (lane 3, Figure 1D ; note the absence of the cathepsin B band, as indicated by the asterisk), but not other cathepsins.
Results
Heat-inactivated controls also showed that all labeled proteins were in fact proteases (data not shown). We did not detect Cathepsins are upregulated during active cathepsins H or S by mass spectrometric sequencing of RIP1-Tag2 tumorigenesis proteins purified from whole tumor lysates with DCG-04, which RIP1-Tag2 transgenic mice develop tumors over time through may reflect much lower expression in the case of cathepsin H. a series of highly reproducible stages . To exHowever, cathepsin S is expressed at higher levels, both in the amine the gene expression changes associated with progreswhole tumors and in sorted inflammatory cells, and yet it was sion through each stage, we performed an Affymetrix microarray not detected as an active enzyme in whole tumor lysates. This profiling experiment on cDNA from pools of normal (nontransdiscrepancy could be attributed to posttranscriptional regulagenic) islets, hyperplastic islets, angiogenic islets, and tumors tion such that mRNA but not active protease was produced; using the 11K and 19K mouse chips (Affymetrix). Following however, we suspect that the activity probe may bind preferenscaling of the hybridization signals for each of the four distinct tially to other cathepsins in the complex tumor lysate. Indeed, stages, data sets were grouped using a self-organizing mapping when the constituent cells were first separated from the whole algorithm (SOM) (Tamayo et al., 1999) into clusters of genes tumors and lysates labeled with the biotinylated ABP, a band showing similar expression patterns (our unpublished data).
corresponding to the molecular weight of active cathepsin S Several cathepsins were found in a SOM cluster that grouped was detected in the infiltrating immune cells (see Figure 3A , genes whose expression was low in normal, hyperplastic, and band labeled I*). Ongoing analyses are expected to address angiogenic islets, and markedly increased in tumors ( Figure 1A) . this possible explanation. Cathepsins H and L were only detectably expressed in tumors,
We next used an ABP to label active proteases in vivo. A whereas cathepsins C and Z were expressed at much higher cell-permeable fluorescent analog of DCG-04 incorporating the levels than in the precursor stages. Two other cathepsins, B BODIPY fluorophore as a tag, BODIPY 530/550-DCG-04 and S, were grouped in another cluster that showed a more (Greenbaum et al., 2002) (Figure 1B ), was injected intravenously gradual upregulation during tumorigenesis ( Figure 1A ). Realinto RIP1-Tag2 mice at different stages of tumor development time, quantitative RT-PCR using primer pairs specific for the ( Figure 2 ). There was little or no cathepsin activity detected by six cathepsin mRNAs was used to evaluate expression in indethe ABP in normal islets (Figures 2A and 2B) , nor in the surpendently isolated pools of normal islets, angiogenic islets, and rounding normal exocrine pancreas, suggesting that the catheptumors. The expression patterns of the six cathepsins in these sins expressed in normal lysosomes and secretory granules distinctive stages were similar to those observed in microarray were either inaccessible to the probe or present at levels below analysis, again indicating upregulation in tumors (our unpubthe threshold of detection. In contrast, cathepsin activity was lished data).
clearly evident in angiogenic islets (Figures 2C and 2D) and To determine if the enzymatic activity of these proteases was tumors ( Figures 2E and 2F ). The cellular localization of cathepsin similarly upregulated during tumorigenesis, we used chemical activity was further resolved by confocal microscopy, as shown probes specific for this family of cysteine cathepsins (Greenin Figures 2I-2K . Labeled cells within the neoplastic lesions baum et al., 2000). These activity-based probes (ABPs) are showed either a punctate perinuclear signal (Figures 2I and based on a small molecule scaffold that binds covalently in the 2J, arrows) or a diffuse activity localization, suggestive of cell active sites of members of the cysteine cathepsin family, thereby membrane-associated activity, and perhaps of cathepsins seallowing their specific identification within cell or tissue lysates.
creted into the extracellular microenvironment (Figures 2I and Furthermore, since the probes bind irreversibly to target prote-2K, arrowheads). We are in the process of further defining the ases in an activity-dependent manner, covalent labeling can be subcellular activity colocalization using cell surface and lysoused as a direct readout of protease activity levels. Using a biotinylated ABP called DCG-04 (Figure 1B ), we detected a somal markers. Interestingly, there was a clear increase in ca- thepsin activity at the invasive edges of the islet carcinomas vealed by differential mobility of the probe-labeled proteases by polyacrylamide gel electrophoresis (PAGE). We then used ( Figures 2G and 2H ), suggestive of a role in tumor invasion.
quantitative RT-PCR to identify the individual cathepsin genes expressed in each flow-sorted cell population, as shown in FigCell type-specific localization of cysteine ure 3B. All six cathepsins were expressed in the infiltrating imcathepsin activity mune cell fraction, with cathepsins B, C, H, and S being differenAs the islet tumors are comprised of multiple cell types, we tially abundant compared to the other cell types. By contrast, sought to identify the cell type(s) responsible for providing cathe tumor cell fraction preferentially expressed the cathepsin thepsin protease activity. Flow cytometry was used to sort the L gene. Two points should be considered when evaluating the solid tumors into three constituent cell types (endothelial, innate relative activity and gene expression profiles in the sorted cell immune, and tumor) as previously described (Bergers et al., types. First, the endothelial and immune cells represent only 2003), and ABP profiling of lysates from the purified cell popula-2%-5% of the total cells inside the tumors, with the overt oncotions was performed using the DCG-04 probe. The labeling of gene transformed ␤ cells constituting the majority ‫,)%59-%09ف(‬ equally loaded samples, consisting of lysates from cell types such that the aggregate contribution of protease activity from isolated and purified by flow cytometry, reveals infiltrating innate immune cells to be a significant source of cathepsin activity the overt tumor cells could be comparable to the apparently higher levels in infiltrating immune cells. Second, the in vivo ABP ( Figure 3A) . Interestingly, the three constituent cell fractions apparently have distinctive cathepsin activity profiles, as rerevealed a focal distribution of high-level activity, particularly tumorigenesis, we used a small molecule inhibitor to block protease activity. The E-64d analog JPM-565 (Bogyo et al., 1999; Meara and Rich, 1996; Shi et al., 1992 ) is a broad-spectrum irreversible inhibitor for the cysteine cathepsin family. The ester associated with the angiogenic vasculature and invasive fronts analog of JPM-565, where the free carboxylic acid has been of carcinomas. These analyses therefore reveal all three cell replaced with an ethyl ester (termed JPM-OEt), is a cell-permetypes to be suppliers of cathepsin activity, but with different able analog of JPM-565 (Bogyo et al., 1999) ( Figure 1B ). This compound was chosen for inhibitor trials due to the increased biases amongst the six genes; as such, cathepsins produced likelihood that it would be able to access intracellular as well as extracellular cathepsin targets. RIP1-Tag2 mice were treated with JPM-OEt in three distinctive trial designs that target different stages in tumorigenesis (Bergers et al., 1999) . In a 5.5 week prevention trial, designed to assess the effects of a test agent on initial angiogenic switching in the normal vasculature of hyperplastic progenitor lesions, daily injection of JPM-OEt produced a 49% reduction in the number of angiogenic islets evident at a defined endpoint (10.5 weeks of age), when solid tumors are just forming ( Figure 4A ) (JPM-OEt, n ϭ 14, and controls, n ϭ 20; p Ͻ 0.0001). In an intervention trial, designed to interfere with the dramatic growth of nascent solid tumors, JPM-OEt reduced cumulative tumor volume by 67% at 14.5 weeks of age, relative to littermate, sham-treated controls (Figure 4B ; n ϭ 19, JPM-OEt-treated; n ϭ 8, n ϭ 16, 11-week and 14.5-week controls respectively; p Ͻ 0.0001). Finally, in a regression trial, designed to test the ability of inhibitors to stabilize or regress large tumors and modestly extend lifespan to a defined endpoint 4 weeks later, JPM-OEt produced "stable disease," in that the tumor volume at the endpoint was comparable to that in mice at the 12-week-old starting point of the trial ( Figure 4B ). Untreated RIP1-Tag2 mice die at 13-15 weeks of age; hence there were no age-matched controls for the JPMOEt mice treated for 4 weeks to the defined endpoint. Therefore, we compared the tumor volumes in 14.5-week-old controls with 16-week-old JPM-OEt-treated mice, revealing a 63% reduction (p Ͻ 0.0001).
To confirm that the effects of JPM-OEt could be specifically attributed to inhibition of cysteine cathepsins, we used the cysteine cathepsin-specific ABPs to assess the inhibition of cathep- Figure 4C , 70%-80%, using NIH Image Tag2 mice (n ϭ 8, n ϭ 8, n ϭ 19, for 11-week, 12-week, and 14.5-week RIP1-software) as measured by residual labeling with the DCG-04
Tag2 controls, respectively. n ϭ 16, and n ϭ 14 for JPM-OEt-treated 14.5-probe. Similarly, cathepsin activity in vivo was also dramatically We then investigated the mechanism responsible for the substantive reduction in both angiogenic switching and tumor volume in JPM-treated mice. The vascularity in angiogenic islets and tumors was assessed by perfusion of a fluorescent-labeled indistinguishable, indicative of alternative pathways to the same lectin through the circulatory system. JPM-OEt-treated angioangiogenic premalignant state. In contrast, many of the JPMgenic islets did not show any obvious differences in vascularizaOEt-treated tumors showed a pronounced reduction in vessel tion, as visualized by the FITC-lectin, compared to control 10.5-density, particularly in the core of larger tumors ( Figure 5D ), as week angiogenic lesions ( Figures 5A and 5B) . Thus, much like compared to the highly vascularized control tumors ( Figure 5C ). analogous studies with an MMP inhibitor and MMP-9 gene
We confirmed the reductions in vascularity by immunostaining knockout mice (Bergers et al., 2000) , fewer hyperplastic islet with two endothelial-selective antibodies, CD31 and MECA32, and observed similar results (data not shown). The particular progenitors switched on angiogenesis, but those that did were OEt-treated tumors, may reflect vessel cooption at the tumor margins from the surrounding normal, exocrine tissue (Holash et al., 1999) . The tumor vasculature was also characterized by a reduction of the effects we attribute to cathepsin activity in pancreatic of vessel branching in JPM-OEt-treated versus untreated tuislet tumorigenesis. mors ( Figures 5E and 5F ), suggesting impairment of endothelial Tumor cell proliferation, as assessed by BrdU incorporation, basement membrane degradation as a result of inhibiting cawas significantly decreased in all stages of RIP1-Tag2 tumorithepsin activity. It is well established that proteolysis of the genesis, particularly in the angiogenic islet stage (Figures 6A-basement membrane is a critical step in vessel sprouting during 6D). There was a 52% reduction in cell proliferation in JPMangiogenesis (Carmeliet, 2003; Kalluri, 2003) , and interestingly, OEt-treated angiogenic islets (p Ͻ 0.0001), while proliferation cathepsin B has been shown to directly degrade three major in JPM-OEt-treated tumors was reduced by 28% in 14.5-week basement membrane components, laminin, collagen IV, and mice (I.T.) (p ϭ 0.01) and 39% in 16-week mice (R.T.) (p Ͻ fibronectin, at physiological pH (Buck et al., 1992) . It is also 0.001), as compared to 14.5-week controls ( Figure 6E ). Since notable that a recent study of a cathepsin S knockout mouse the vasculature in the angiogenic islets of JPM-OEt-treated mice implicated cathepsin S as an enhancer of angiogenesis associwas indistinguishable from that of controls (albeit less frequent), ated with wound healing in the skin (Shi et al., 2003) , suggesting that it in particular may be involved in the angiogenic component the reduced proliferation index suggests that JPM-OEt is di-rectly interfering with tumor cell growth. Thus we imagine a direct role for cysteine cathepsins in facilitating proliferation of the oncogene-expressing ␤ cells, in addition to effecting a robust tumor vasculature. In contrast to the effects on cell proliferation, inhibition of cathepsin activity with JPM-OEt had no discernible impact on the frequency of apoptosis (data not shown). While certain cathepsins have been shown to be involved in mediating apoptosis triggered by specific stimuli (e.g., TNF-induced apoptosis [Foghsgaard et al., 2001] ), the pharmacological trials with JPMOEt indicate that cathepsins are not centrally involved in the acquired resistance to apoptosis that is demonstrably important in this islet tumorigenesis model (Christofori et al., 1994; Naik et al., 1996) .
Cathepsins contribute to the capability for invasive growth
The in vivo ABP revealed a focal increase in cathepsin activity at the invasive edges of tumors ( Figures 2G and 2H) , suggesting a role in facilitating local tumor invasion. Consistent with this hypothesis, daily treatment of RIP1-Tag2 mice with JPM-OEt significantly delayed progression to both widely invasive (IC-2) and microinvasive (IC-1) carcinomas in both intervention (I.T.) and regression trials (R.T.) ( Figure 7G ). Detailed grading of hematoxylin and eosin-stained tumors (Lopez and Hanahan, 2002) showed that mice treated in an intervention trial with JPM-OEt had no high-grade IC-2 class carcinomas, producing a clear and significant shift toward more benign, encapsulated tumors (representative images shown in Figures 7A and 7B) . When starting the treatment regimen later, in a regression trial at 12 weeks (where carcinomas have already formed), JPM-OEt significantly reduced but did not abolish the incidence of invasive tumors of both classes at 16 weeks. Since the epithelial cellcell interaction molecule E-cadherin is characteristically downregulated upon progression to carcinomas (Perl et al., 1998; Vleminckx et al., 1991) , in particular in the RIP1-Tag2 model, we used it as an independent criterion for the invasive growth capability, to complement the grading of H&E stained sections; to that end, tumors from JPM-OEt-treated and control RIP1-Tag2 mice were immunostained with antibodies for E-cadherin. There was a complete concordance with the histological grading of invasion: we detected no tumors that lacked E-cadherin expression altogether (IC-2) following an I.T., and saw reduced have used the fluorescent ABP to visualize in vivo activity in another mouse model of human cervical cancer. These transgenic mice express the human papillomavirus type 16 oncogenes under the keratin 14 promoter and develop invasive can-localized to the stroma underlying the dysplastic epidermis (Figure 8C) , and was seen throughout the cervical tumors ( Figure  8D ). Higher magnification of both the dysplastic ( Figure 8E ) and cancerous ( Figures 8F and 8G ) lesions revealed a similar activity localization to that seen in the lesional pancreas of RIP1-Tag2 mice, associated both with the cell surface of endothelial cells ( Figure 8F ) and with punctate perinuclear regions of individual cells within the tumor ( Figure 8G ).
Discussion
In this study, activity-based probes and a class-specific small molecule inhibitor were used to investigate the functional importance of the cathepsin cysteine proteases in cancer. We found that several cathepsins were upregulated during tumor progression and then demonstrated their functional involvement in a prototypical mouse model of pancreatic islet cell cancer. Of the eleven known mammalian cysteine cathepsins (Turk et al., 2002) , expression of six mouse cathepsin genes was upregulated during RIP1-Tag2 tumorigenesis. Four of these cathepsins (B, C, L, and Z) were specifically identified as being substantively increased in their protease activity in solid tumors. The potential of reporter substrates to probe protease activity in tumors in vivo has previously been demonstrated (Bremer et al., 2001; Tung et al., 2000) using xenografts of human cancer cell lines that expressed high levels of the candidate proteases. While illustrative, the experimental design did not allow for evaluation of the endogenous proteases within a tumor or its constituent cell types. Furthermore, this method does not allow for the biochemical analysis of target proteases contributing to hydrolysis of we demonstrate that the proteases involved can be identified A: The cervix in an estrogen-treated FVB/n control mouse did not evidence and monitored biochemically. sin cysteine proteases are inhibited is of particular interest.
E-G: Higher magnification of a dysplastic lesion (E) reveals both cell-associ-
Cathepsins have been proposed to function in the initiating ated punctate activity and colocalization with the angiogenic vasculature, steps of a proteolytic cascade involving serine proteases and as is also the case in tumors (F and G, respectively). The scale bar corresponds to 50 M in A-E and 25 M in F-G. Koblinski et al., 2000; Rao, 2003) . However, both individual gene knockouts of members of the MMP and serine protease family (MMP-2, MMP-9 and uPA) and broadspectrum MMP inhibition did not affect progression to invasive cers in the context of sustained estrogen levels (K14-HPV/E 2 ) carcinomas in this model (Bergers et al., 2000) . We propose, via a series of lesional stages analogous to those in humans therefore, that the cathepsins are facilitating the invasive growth (Arbeit et al., 1996; Elson et al., 2000) . The K14-HPV/E 2 mice capability, a hallmark of malignancy, through a distinctive pathevidence a similar angiogenic switch to that observed in RIP1-way. One attractive mechanism would involve proteolysis of Tag2 mice and in the human cervix (Smith-McCune et al., 1997) , E-cadherin, given that loss of E-cadherin function is a determiwith intense angiogenesis underlying advanced dysplasias (CIN nant of the invasive growth capability in this (Perl et al., 1998) 3) and invasive carcinomas. No cysteine cathepsin activity was and other tumors (Strathdee, 2002; Vleminckx et al., 1991) , and detected in the normal cervix of control female mice (FVB/n/ that extracellular proteolysis has been implicated as one means E 2 ) following intravenous injection of the fluorescent cysteine to abolish its function (Ito et al., 1999; Rios-Doria et al., 2003) ; cathepsin ABP ( Figure 8A ). In contrast, K14-HPV/E 2 mice bearthis possibility is the subject of ongoing investigation. ing CIN-3 dysplasias or tumors revealed significant levels of Evaluation of the constituent cell types purified from tumors by flow cytometry (using both quantitative RT-PCR and ABPs) cysteine cathepsin activity. In the CIN-3 lesions, activity was revealed that the candidate cathepsin genes were most promimor-modulatory responses attributed to the cystatins in other experimental systems. In any event, the cystatins warrant connently expressed in innate immune cell types (granulocytes and macrophages), as well as in endothelial and tumor cells. Three sideration along with the cathepsins as factors influencing tumor phenotypes in mouse models and in human cancers. of the six genes were expressed in all three cell fractions, while cathepsins C and H were selectively expressed by immune
MMPs (reviewed in
In conclusion, with the evidence presented here, perhaps cysteine cathepsin inhibitors such as JPM-OEt (which shows cells, and cathepsin L was preferentially expressed in the tumor cell compartment. This multiplicity of sources for cathepsin acefficacy and no apparent toxicity in the trials performed in this mouse model), or vinyl sulfone peptidomimetics (e.g., N-methyl tivity is provocative: perhaps different cell types are contributing cathepsins required to manifest distinct functions among the set piperazine-Phe-hPhe-vinyl sulfone phenyl, which is entering clinical trials for Chagas disease [Engel et al., 1998 ; McKerrow we have attributed by their collective pharmacological inhibition. The prominence of expression of the implicated cathepsin genes et al., 1999]), should be considered for clinical trials treating cancers known to upregulate these proteases. It is reasonable by innate immune cells adds further weight to the growing consensus that immune infiltrates have the potential to be tumorto suggest that cathepsin inhibitors may show combinatorial benefits with other targeted (and traditional) therapies, which enhancing (Coussens and Werb, 2002) . Indeed, we have previously shown that MMP-9, a matrix metalloprotease, is supplied could be revealed in preclinical trials involving this and other mouse models of human cancer. exclusively by infiltrating innate immune cells in the RIP1- Tag2 The generation of RIP1-Tag2 mice as a model of pancreatic islet cell carcinoconstituent cell types within islet tumors, and have a crucial, genesis has been previously reported . Similarly, the generanonoverlapping function to that of the MMPs, in facilitating protion of K14-HPV16 transgenic mice (Coussens et al., 1996) and their treatment with 17␤-estradiol (E 2 ) for cervical carcinogenesis has been reported gression to the invasive carcinoma stage. (Arbeit et al., 1996; Elson et al., 2000) . Mice were maintained in accordance Taken together, the data raise important questions for the with the University of California, San Francisco (UCSF) institutional guidelines future. Which individual cathepsin genes are important for the governing the care of laboratory mice.
various ascribable functions during tumorigenesis? What cell type(s) contributes the necessary activity for each of these capa-
Microarray and real-time quantitative PCR
bilities? Both cathepsin gene knockout mice and cathepsin subNormal (nontransgenic BL/6) and hyperplastic islets (from 5-week-old RIP1-Tag2 mice) were collected as previously described (Parangi et al., 1995) .
type-selective inhibitors should provide avenues to address Angiogenic islets were isolated from 8-week-old RIP1-Tag2 mice by collathese questions. A broader issue is the prevalence of cathepsin genase digestion of the excised pancreas, and selected based on their red, upregulation in other types of cancer, a question we have begun hemorrhagic appearance (Parangi et al., 1995) . Tumors were microdissected to evaluate in another mouse model of cancer, the K14-HPV/E 2 from the excised pancreas of 13-week-old RIP1-Tag2 mice and the surmodel of cervical carcinoma. Interestingly, we observed a similar rounding exocrine tissue carefully removed. RNA was prepared from pools induction of cysteine cathepsin activity that was not evident in of snap-frozen islets and tumors using an RNeasy kit (Qiagen), DNase treated, and LiCl precipitated. 10 g of total RNA was used in cDNA synthethe normal cervix, by using the in vivo ABP. Cathepsin activity sis, and labeled cRNA subsequently generated using standard protocols. appeared concomitant with the angiogenic switch in the dysMicroarray hybridizations to the mouse 11K and 19K chips and measurement plastic lesions and was maintained in tumors, much as we had of hybridization intensities were carried out according to manufacturer's observed in the RIP1-Tag2 model. Future functional studies in protocols (Affymetrix Inc). Each data set was rescaled to normalize for differthis and other models should provide insight into the general ences of microarray intensities across the different sets. This scaled data involvement of cysteine cathepsins in tumor development in was then analyzed using self-organizing map (SOM) (Tamayo et al., 1999) other organs. functions independent of their role as cysteine cathepsin inhiNormal islets, angiogenic islets, and tumors were collected as above and bitors (Shridhar et al., 2003) . These cathepsin-independent homogenized in lysis buffer (5 mM acetate [pH 5.5], 1 mM EDTA, 2 mM DTT, 0.1% Triton X-100), and protein concentrations quantitated using the functions may, or may not, be contributing to the complex tu-Bradford assay. The lysates were labeled with DCG-04 and equally loaded non, and Z. Werb for helpful and insightful suggestions to the manuscript. This research was supported by the Leukemia and Lymphoma Society and analyzed by gel electrophoresis as previously described (Greenbaum et al., 2000) . ). RIP1-Tag2 mice at different ages (8 weeks and 13 weeks) and control C57Bl/ 6J mice were anesthetized with an intraperitoneal injection of 2.5% avertin. Mice were individually weighed and BODIPY530/550-DCG-04 (1 mM solution in 10 mM HEPES [pH 7.4]; 10% DMSO w/v) was intravenously injected through the tail vein (volume to be injected in l ϭ 5ϫ mouse weight in sucrose, followed by embedding in OCT compound. Frozen sections were cut at 10 m thickness, rinsed in PBS, and covered with Vectashield with References DAPI (Vector) to visualize nuclei. At least five mice per age group were analyzed. K14-HPV/E2 mice were similarly analyzed at two different stages:
Arbeit, J.M., Howley, P.M., and Hanahan, D. (1996) . Chronic estrogenwhen they typically have CIN-3 dysplasia (5 months of age) or tumors induced cervical and vaginal squamous carcinogenesis in human papillo-(7 months of age). FVB/n mice treated with estrogen were used as controls mavirus type 16 transgenic mice. Proc. Natl. Acad. Sci. USA 93, 2930-2935. and three mice per group (control, dysplasia, and tumor-bearing) were inBalaji, K.N., Schaschke, N., Machleidt, W., Catalfamo, M., and Henkart, jected with the BODIPY ABP as detailed above, and the cervix was removed P. A. (2002) . Surface cathepsin B protects cytotoxic lymphocytes from selfand processed as above.
destruction after degranulation. J. Exp. Med. 196, [493] [494] [495] [496] [497] [498] [499] [500] [501] [502] [503] .
Flow cytometry
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Pharmacological trials of the JPM cathepsin inhibitors
The dosing regimen for the three different RIP1-Tag2 trials was determined Bogyo, M., Verhelst, S., Bellingard-Dubouchaud, V., Toba, S., and by injection of various concentrations of JPM-OEt (10, 25, 50, or 100 mg/ Greenbaum, D. (1999) . Selective targeting of lysosomal cysteine proteases kg/day) for 5 days, followed by injection of the BODIPY530/550-DCG-04 with radiolabeled electrophilic substrate analogs. Chem. Biol. 7, 27-38. probe and PAGE analysis to assess the reductions in protease activity (unBremer, C., Tung, C.H., and Weissleder, R. (2001) . In vivo molecular target published data). 50 mg/kg/day as a single daily intraperitoneal injection was assessment of matrix metalloproteinase inhibition. Nat. Med. 7, 743-748. determined to be the optimal dose and used for all in vivo studies, and JPMOEt was administered in 30% DMSO/70% PBS. Independent trials were Brix, K., Linke, M., Tepel, C., and Herzog, V. (2001) . Cysteine proteinases performed at least twice on groups containing equal numbers of male and mediate extracellular prohormone processing in the thyroid. Biol. Chem. female RIP1-Tag2 mice. Control littermates were treated with 30% DMSO/ 382, 717-725. 70% PBS. All in vitro and in vivo analysis of cathepsin activity using the Buck, M.R., Karustis, D.G., Day, N.A., Honn, K.V., and Sloane, B.F. (1992) . ABPs was performed 6 hr after the final injection of JPM-OEt. Tumor volume Degradation of extracellular-matrix proteins by human cathepsin B from and angiogenic islet quantitation were performed as previously described normal and tumour tissues. Biochem. J. 282, 273-278. (Bergers et al., 1999; Inoue et al., 2002) , and the Wilcoxon t test was used for statistical analyses and calculation of means and SEM. All animal studies Carmeliet, P. (2003) . Angiogenesis in health and disease. Nat. Med. 9, 653-660. were performed using protocols approved by the animal care and utilization Christofori, G., Naik, P., and Hanahan, D. (1994) . A second signal supplied committee at the University of California at San Francisco.
by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369, 414-418. Tissue preparation and immunohistochemistry Tissues were prepared as previously described for frozen and paraffin emCoussens, L.M., and Werb, Z. (2002) . Inflammation and cancer. Nature 420, bedding (Lopez and Hanahan, 2002) . FITC-lectin (Inoue et al., 2002) BrdU, 860-867. TUNEL and E-cadherin staining, and H&E grading (Lopez and Hanahan, Coussens, L.M., Hanahan, D., and Arbeit, J.M. (1996) . Genetic predisposition 2002) were performed as previously described. For BrdU and TUNEL quantiand parameters of malignant progression in K14-HPV16 transgenic mice. tation, at least 5 graded lesions per mouse (typically 10-15), and at least 5 Am. J. Pathol. 149, 1899-1917. mice per age-matched group were counted blindly, subsequently decoded, and statistical analysis performed. 
